Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Locally Advanced Inoperable Breast Cancer- A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY).

International journal of radiation oncology, biology, physics·2026
Same author

Oral microbiota in early- and late-onset tongue cancers: A pilot case-control study.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Consensus-based recommendations for optimizing perioperative nutritional support and muscle health in major surgery in India.

Frontiers in nutrition·2025
Same author

Unravelling the Hidden Complication: Costal Osteomyelitis of the PMMC Donor Site.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2025
Same author

The Macroeconomics of Corporate Debt.

The review of corporate finance studies·2025
Same author

Demystifying the conundrum of medullary thyroid cancers and providing a brief review of literature.

Indian journal of cancer·2025

Related Experiment Video

Updated: May 19, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Targetable "driver" mutations in non small cell lung cancer.

R Vijayalakshmi1, Arvind Krishnamurthy

  • 1Cancer Institute, Chennai, Tamil Nadu India.

Indian Journal of Surgical Oncology
|September 4, 2012
PubMed
Summary

Identifying specific gene mutations in lung cancer patients can guide personalized therapy. This approach promises better treatment outcomes by targeting tumor-specific molecular alterations, moving beyond traditional chemotherapy.

Keywords:
Driver mutationsMolecular profiling based on mutationsPersonalized therapy

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 19, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Conventional chemotherapy offers limited survival benefits.
  • Advances in understanding molecular pathogenesis reveal specific targets for treatment.

Purpose of the Study:

  • To review driver mutations in lung tumorigenesis.
  • To highlight the potential of molecular targeted therapeutics.
  • To emphasize personalized therapy based on patient mutation profiles.

Main Methods:

  • Review of recent studies on lung cancer driver mutations.
  • Analysis of clinically relevant translational advances in specific genes.
  • Discussion of mutations including EML4-ALK, HER2, PIK3CA, AKT, BRAF, MAP2K1, MET, EGFR, and KRAS.

Main Results:

  • The Lung Cancer Mutation Consortium (LCMC) identified driver mutations in nearly two-thirds of advanced lung cancer patients.
  • Molecular targeted therapeutics can be guided by identified driver mutations.
  • Mutation profiling can supplement tumor histology in treatment decisions.

Conclusions:

  • Personalized therapy based on individual mutation profiles holds significant promise for lung cancer treatment.
  • Targeting specific gene mutations offers a more effective strategy than traditional approaches.
  • Future lung cancer management should integrate mutation profiling with histology for directed therapy.